SKW Schwarz advised Dreieich-based Biotest AG on agreements to support the PEPPER study.
The study is a multi-center, randomized, controlled study with Pentaglobin® in peritonitis conducted by University of Aachen. The study investigates personalized treatment approaches with Pentaglobin® by Biotest. It will also test new types of test systems to determine the individual risk.
At a total mortality rate of more than 30%, peritonitis is one of the most dangerous diseases in intensive care units. Since only antibiotics and surgical interventions are currently available for the treatment of devastating systemic infections and subsequent inflammations, personalized treatments are urgently needed to normalize the immune response and to combat inflammatory misregulation.
The results of this study may be an important step towards a more personalized and therefore more successful treatment of peritonitis.
Curetis GmbH for molecular diagnostic analyses and Sphingotec GmbH for the determination of diagnostic parameters are also partners in the study.
An SKW Schwarz team, led by partner Dr. Kolja Petrovicki, advised Biotest AG on the agreements with University of Aachen, Curetis GmbH, and Sphingotec GmbH.
Counsel to Biotest AG: Dr. Kolja Petrovicki, LL.M. (UPenn), (Corporate/M&A, Partner), Dr. Klaus Jankowski (Public Law, Partner)